Business
Precipio Signs First IV-Cell Customer Agreement
Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty
About this update from Precipio, Inc.
[{"type":"text","content":"Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential\nNEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida, has completed its validation of Precipio’s proprietary IV-Cell® culture media, and will adopt the product for use in its clinical cytogenetics laboratory. The adoption of IV-Cell by industry leader AON demonstrates Precipio’s ability to identify a critical unmet market need, develop and bring to market a differentiated, high value solution to the customer. Previous launch of HemeScreen® testing by AON in August 2021, combined with this agreement for IV-Cell serve as validation of Precipio’s new strategic business model as a specialty cancer diagnostics products company, and its ability to deliver multiple products to the same customer. Jacob Diaz, AON’s Laboratory Operations Manager said, “IV-Cell will provide significant technical and operational efficiencies within our laboratory as well as help AON provide a more accurate diagnosis to patients.” “We are dedicated to building our relationship with AON as we continue to innovate and commercialize our portfolio of high value, differentiated, diagnostic products like HemeScreen. AON’s adoption of this technology solidifies their innovative and leadership position within the market,” said Ilan Danieli, CEO of Precipio. “We are excited for the gradual reopening of laboratories, which enables us to meet with customers in-person and demonstrate the clinical and operational benefits of IV-Cell media within their laboratory, leading to further market penetration both domestically and internationally.” About IV-Cell® Media Precipio’s IV-Cell® culturing media is a critical reagent intended to be used by cytogenetics laboratories to simplify, speed up and provide greater accuracy of their hematologic (blood cancer) diagnostic processes. IV-Cell includes all the necessary components for the cell culturing process. It simplifies the process by eliminating the need to cocktail a media mix for each sample, and provides cytogenetics laboratories with both clinical, operational and economic advantages relative to the existing products on the market. For more information please visit our website at http://www...